- Home
- ABOS vs NYXH Comparison
ABOS vs NYXH Comparison
Compare ABOS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABOS | NYXH |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.9M | 161.9M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ABOS | NYXH |
|---|---|---|
| Price | $2.15 | $1.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.00 | ★ $9.33 |
| AVG Volume (30 Days) | ★ 620.2K | 182.6K |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $1.26 |
| 52 Week High | $3.60 | $8.59 |
Technical Indicators
Market Signals| Indicator | ABOS | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 38.40 | 28.03 |
| Support Level | $2.13 | $1.26 |
| Resistance Level | $2.43 | $1.70 |
| Average True Range (ATR) | 0.16 | 0.09 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 6.12 | 4.55 |
Price Performance
Historical ComparisonAbout ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.